Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Sofosbuvir/ledipasvir safe and effective for genotype 1 HCV

A single-tablet regimen containing the hepatitis C virus (HCV) nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir - the combination in Gilead Science's recently approved Harvoni pill - was well-tolerated and cured 97% of patients with HCV genotype 1 in the Phase

Published
16 hours ago
By
Liz Highleyman
HCV sexual transmission: HIV negative may be at risk, more awareness and testing needed

Hepatitis C virus (HCV) is known to be sexually transmitted among HIV positive men who have sex with men, but HIV negative men may be at risk as well, according to recent reports. Other recent studies have looked at awareness of HCV sexual transmission and screening practices, suggesting that improvement is needed in both areas.

Published
16 October 2014
From
HIVandHepatitis.com
Coffee, Even Decaf, May Promote Liver Health

Drinking coffee, whether decaffeinated or regular, is linked to healthier levels on tests indicating liver function.

Published
16 October 2014
From
AIDSMeds
IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials

AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek 2014 last week in Philadelphia. Serious side effects were uncommon and few people discontinued treatment for this reason.

Published
16 October 2014
From
HIVandHepatitis.com
Unique 'pay if you clear' proposal for new hepatitis drug

The NHS in Scotland could be reimbursed for the cost of a new hepatitis drug if sufferers fail to clear the virus. The novel proposal was revealed after the drug Olysio was cleared for use by the Scottish Medicines Consortium (SMC).

Published
15 October 2014
From
BBC
Egypt: Poor infection control to blame for hepatitis C epidemic

Country-wide campaigns to combat schistosomiasis in the 1960’s and 70’s may not be the major cause of the Egypt’s hepatitis C epidemic. Widespread breaches of hygiene in medical care are largely responsible.

Published
15 October 2014
From
Nature Middle East
Fair Pricing Coalition Urges a Uniform Price for Curative Hepatitis C Treatment

The $63,000 wholesale acquisition cost (WAC) for eight weeks of Harvoni™ (sofosbuvir and ledipasvir) should be extended to 12 and 24-week curative treatment durations.

Published
15 October 2014
From
Fair Pricing Coalition
If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?

Now that the FDA has approved the Harvoni treatment from Gilead Sciences and a $94,500 price for a 12-week regimen has been established, attention is turning toward AbbVie and the steps the big drug maker must take to win market share. Already, though, some Wall Street prognosticators believe AbbVie may find it daunting.

Published
15 October 2014
From
Wall Street Journal
HCV core-antigen testing is a reliable way of detecting acute HCV infections in HIV-positive gay men

Hepatitis C virus (HCV) core-antigen testing is a highly reliable way of diagnosing acute HCV infections in people living with HIV, investigators from the United Kingdom report

Published
13 October 2014
By
Michael Carter
As Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles

As Gilead Sciences launches its next generation Hepatitis C pill, Harvoni, Medicaid programs are bracing for another extraordinary wave of costs, with 70 percent of states implementing coverage restrictions.

Published
10 October 2014
From
Forbes
← First12345...145Next →

Filter by country